An autocrine growth factor constitutively produced by a human lymphoblastoid B-cell line is serologically related to lymphotoxin (TNF-beta). 1989

T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
Koltzov Instiute of Developmental Biology, Academy of Sciences of the USSR, Moscow.

Conditioned medium of a human lymphoblastoid B-cell line RPMI-6410t contains a factor sufficient for maintainance and growth of these cells. At the same time RPMI-6410t cells secrete a soluble factor cytotoxic towards mouse L929 cells. Production of these activities by RPMI-6410t cell line and its subclones is significantly enhanced after activation with phorbol mirystate acetate (PMA). Both activities can be neutralized by antiserum raised against recombinant lymphotoxin (rTNF-beta) but not by antibodies against tumor necrosis factor (rTNF-alpha). Northern analysis showed the presence of lymphotoxin mRNA which is further induced after PMA treatment. These data suggest that both autocrine growth factor and cytotoxic activities correspond to the same molecule(s) probably identical to 25 kD lymphotoxin (TNF-beta).

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013755 Tetradecanoylphorbol Acetate A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA. Phorbol Myristate Acetate,12-Myristoyl-13-acetylphorbol,12-O-Tetradecanoyl Phorbol 13-Acetate,Tetradecanoylphorbol Acetate, 4a alpha-Isomer,12 Myristoyl 13 acetylphorbol,12 O Tetradecanoyl Phorbol 13 Acetate,13-Acetate, 12-O-Tetradecanoyl Phorbol,Acetate, Phorbol Myristate,Acetate, Tetradecanoylphorbol,Myristate Acetate, Phorbol,Phorbol 13-Acetate, 12-O-Tetradecanoyl,Tetradecanoylphorbol Acetate, 4a alpha Isomer
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
April 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
November 1990, The Journal of biological chemistry,
T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
March 1993, The Journal of experimental medicine,
T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
November 1989, Archives of biochemistry and biophysics,
T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
October 1982, Cellular immunology,
T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
April 1998, Leukemia,
T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
January 1993, Cancer letters,
T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
January 1984, The Journal of biological chemistry,
T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
November 1987, Science (New York, N.Y.),
T M Seregina, and M I Mekshenkov, and R L Turetskaya, and S A Nedospasov
September 1988, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
Copied contents to your clipboard!